Nordic Life Science 1
REAL-WORLD EVIDENCE // THE NORDICS Team NordicRWE
”ARTIFICIAL INTELLIGENCE, LARGE LANGUAGE MODELS, AND ADVANCED STATISTICS WILL DRIVE PROGRESS WITHIN THE FIELD.” addition to that, we are joining a community built upon a dare-to-share culture, so we can collaborate and share resources with member companies and learn from each other,” says Christian Jonasson, Research Director at Nordic RWE. “RWE is pivotal in advancing evidence-based medicine, bridging the gap between clinical research and practice. Partnering with stakeholders across the healthcare community to drive evidencebased medicine is crucial in our pursuit of better healthcare outcomes. NordicRWE’s dedication to data-driven drug development aligns with our vision. We are looking forward to learning more, collaborating, maximizing RWD assets, driving innovation, and addressing unmet medical needs,” stated Nina Mian, Executive Director, Head of Data Science & Advanced Analytics, AstraZeneca, at the time of the announcement. The Nordic challenge There has been increasing interest in RWE from the pharma industry and governmental bodies, and Thoresen and Jonasson strongly believe that RWE can be used in drug development, both as control arms in clinical studies and also in the area of signal detection. “We believe that governmental bodies will use more RWE in their HTA process and in post-marketing and effectiveness studies,” says Jonasson. The possibilities of RWE are obvious, Jonasson says, “Artificial intelligence (AI), large language models (LLM), and advanced statistics will drive progress within the field.” Access to and sharing of data between countries will be barriers to RWE reaching its full potential in the Nordics, Thoresen adds. “The Nordic challenge can only be solved through political decisions and new legislation. This could include linking individual registers, for example for cancer diagnostics and treatment. Health technology assessments (HTA) for the implementation of innovative new medicine could be faster and more accurate using Nordic RWE data,” Thoresen concludes. NLS FACTS REAL-WORLD EVIDENCE Real-World Evidence (RWE) originates from the analysis of Real-World Data (RWD), which is patient and health data that comes from an array of sources, but not from conventional clinical trials. These sources could be electronic health records, disease registries, patientgenerated data (including in home-use settings), and data gathered from other sources, such as mobile devices, that can provide information on health status. In short, RWE encompasses the insights generated when this data is analyzed. NORDICLIFESCIENCE.ORG | 81 PHOTO GORM K GAARE